Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 3
NL-OMON58791Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide and semaglutide in cardiac morbidity, obesity, Overweight and 1 more (2 arms), sponsored by Novo Nordisk. Started Apr 2023; status: active, not recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
cardiac morbidityobesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON58791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58791.